<p>MBX Biosciences, Inc.（纳斯达克代码：MBX - 获取免费报告）的股票在周二交易中下跌了 8.8%。该公司的股价最低曾达到 35.87 美元，最后交易价为 36.5370 美元。在午盘交易中，约有 708,034 股被交易，较平均每日交易量 614,707 股增加了 15%。该股票此前收盘价为 40.08 美元。</p>
<p>获取 <strong>MBX Biosciences</strong> 的提醒：</p>
<h2>更多 MBX Biosciences 新闻</h2>
<p>以下是本周影响 MBX Biosciences 的主要新闻：</p>
<ul>
<li>积极情绪：Citizens JMP 将 MBX Biosciences 的目标价从 76 美元上调至 86 美元，并重申了 <strong>市场表现优于大盘</strong> 的评级，表明当前水平有显著上行空间。Citizens JMP 上调 MBX Biosciences 目标价</li>
<li>积极情绪：Truist Financial 也将其目标价从 50 美元上调至 70 美元，并维持 <strong>买入</strong> 评级，进一步增强了分析师对该股票的乐观情绪。Truist 上调 MBX Biosciences 目标价</li>
<li>积极情绪：MBX 发布了肥胖组合的更新，显示 MBX-4291 的早期第一阶段数据，包括第一组在 8 周内平均减重 7% 的结果，并支持潜在的每月一次给药，这可能增强投资者对公司管线的信心。MBX 肥胖组合更新和第一阶段数据</li>
<li>中性情绪：Lifesci Capital 做出了混合的预测调整：它将一些 2026 年季度预估下调，同时上调了第二季度的预估，并保持 <strong>强买</strong> 评级。这些修订表明预期仍在演变，但该公司整体上仍持建设性态度。</li>
</ul>
<h2>分析师评级上调与下调</h2>
<p>多位股票分析师对 MBX 股票发表了评论。Weiss Ratings 在 4 月 21 日的报告中重申了对 MBX Biosciences 股票的 &#34;卖出（d-）&#34; 评级。花旗集团在周二的研究报告中重申了对 MBX Biosciences 股票的 &#34;跑赢大盘&#34; 评级。Lifesci Capital 在 3 月 31 日的研究报告中将 MBX Biosciences 股票的评级上调至 &#34;强买&#34;。TD Cowen 在 3 月 12 日的研究报告中重申了对 MBX Biosciences 股票的 &#34;买入&#34; 评级。最后，巴克莱在周二的研究报告中将 MBX Biosciences 股票的目标价从 66.00 美元上调至 70.00 美元，并给予该公司 &#34;增持&#34; 评级。一位投资分析师对该股票给予了强买评级，十位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 60.22 美元。</p>
<p><strong>查看我们最新的 MBX 股票报告</strong></p>
<h2>MBX Biosciences 股票表现</h2>
<p>该公司的市值为 17.6 亿美元，市盈率为-16.74，贝塔值为 0.78。该公司的 50 日移动平均价格为 31.18 美元，200 日移动平均价格为 31.40 美元。</p>
<p>MBX Biosciences（纳斯达克代码：MBX - 获取免费报告）最近在 3 月 12 日发布了其财报。该公司报告每股收益（EPS）为-0.49 美元，超出分析师的共识预期-0.64 美元，超出幅度为 0.15 美元。分析师平均预测 MBX Biosciences, Inc. 本财年每股收益为-2.9 美元。</p>
<h2>MBX Biosciences 的内部买卖</h2>
<p>在其他 MBX Biosciences 的新闻中，首席执行官 P. Kent Hawryluk 于 3 月 13 日收购了 18,500 股该股票。该股票的收购均价为每股 28.41 美元，总价值为 525,585.00 美元。交易后，首席执行官直接持有该公司 486,777 股股票，价值约为 13,829,334.57 美元。这代表了其持股比例的 3.95% 的增长。该收购在向证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
<h2>机构投资者对 MBX Biosciences 的看法</h2>
<p>多家机构投资者最近调整了对 MBX 的持股。Geode Capital Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前拥有 348,447 股该公司股票，价值 397.6 万美元，此前在上个季度又购买了 73,989 股。Rhumbline Advisers 在第二季度将其在 MBX Biosciences 的持股增加了 171.6%。Rhumbline Advisers 目前拥有 23,662 股该公司股票，价值 27 万美元，此前在上个季度又购买了 14,950 股。XTX Topco Ltd 在第二季度购买了价值约 135,000 美元的 MBX Biosciences 新股份。制造商人寿保险公司在第二季度将其在 MBX Biosciences 的持股增加了 73.8%。制造商人寿保险公司目前拥有 87,097 股该公司股票，价值 994,000 美元，此前在上个季度又购买了 36,987 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 MBX Biosciences 的持股增加了 40.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 9,329 股该公司股票，价值 106,000 美元，此前在上个季度又购买了 2,682 股。</p>
<h2>MBX Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>我们是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢疾病的新型精准肽疗法。我们的公司由全球领先的专家创立，采用变革性的方法进行肽药物的设计和开发。利用这一专业知识，我们设计了专有的精准内分泌肽™（PEPTM）平台，以克服未修饰和修饰肽疗法的关键限制，并改善临床结果，简化患者的疾病管理。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 MBX Biosciences</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳而暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大幅上涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元于 MBX Biosciences 吗？</h2>
<p>在考虑 MBX Biosciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MBX Biosciences 并不在名单上。</p>
<p>虽然 MBX Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>MBX Biosciences（纳斯达克代码：MBX）股价下跌 8.8%，至 36.54 美元，交易量增加。分析师们依然持乐观态度，Citizens JMP 将其目标价上调至 86 美元，Truist Financial 则上调至 70 美元，均维持积极评级。该公司报告了其肥胖药物 MBX-4291 的有希望的第一阶段数据。尽管 Lifesci Capital 的预测存在分歧，但整体情绪依然看涨，市场共识评级为 “适度买入”，平均目标价为 60.22 美元。首席执行官 P. Kent Hawryluk 最近增加了在公司的持股，购买了 18,500 股</p>

<p>Shares of MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) were down 8.8% during trading on Tuesday . The company traded as low as $35.87 and last traded at $36.5370. Approximately 708,034 shares were traded during mid-day trading, an increase of 15% from the average daily volume of 614,707 shares. The stock had previously closed at $40.08.</p>
<div class="lb-trans"><p>MBX Biosciences, Inc.（纳斯达克代码：MBX - 获取免费报告）的股票在周二交易中下跌了 8.8%。该公司的股价最低曾达到 35.87 美元，最后交易价为 36.5370 美元。在午盘交易中，约有 708,034 股被交易，较平均每日交易量 614,707 股增加了 15%。该股票此前收盘价为 40.08 美元。</p>
</div><p>Get <strong>MBX Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MBX Biosciences</strong> 的提醒：</p>
</div><h2>More MBX Biosciences News</h2>
<div class="lb-trans"><h2>更多 MBX Biosciences 新闻</h2>
</div><p>Here are the key news stories impacting MBX Biosciences this week:</p>
<div class="lb-trans"><p>以下是本周影响 MBX Biosciences 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Citizens JMP raised its price target on MBX Biosciences to $86 from $76 and reiterated a <strong>market outperform</strong> rating, signaling substantial upside from current levels. Citizens JMP price target raised on MBX Biosciences</li>
<li>Positive Sentiment: Truist Financial also boosted its price target to $70 from $50 and maintained a <strong>buy</strong> rating, adding to the bullish analyst sentiment around the stock. Truist raises MBX Biosciences price target</li>
<li>Positive Sentiment: MBX released an obesity portfolio update showing early Phase 1 data for MBX-4291, including mean weight loss of 7% at 8 weeks in the first cohort and support for potential once-monthly dosing, which could strengthen investor confidence in the company’s pipeline. MBX obesity portfolio update and Phase 1 data</li>
<li>Neutral Sentiment: Lifesci Capital made mixed forecast changes: it nudged some 2026 quarterly estimates lower while raising its Q2 estimate and keeping a <strong>Strong-Buy</strong> rating. The revisions suggest expectations are still evolving, but the firm remains constructive overall.</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Citizens JMP 将 MBX Biosciences 的目标价从 76 美元上调至 86 美元，并重申了 <strong>市场表现优于大盘</strong> 的评级，表明当前水平有显著上行空间。Citizens JMP 上调 MBX Biosciences 目标价</li>
<li>积极情绪：Truist Financial 也将其目标价从 50 美元上调至 70 美元，并维持 <strong>买入</strong> 评级，进一步增强了分析师对该股票的乐观情绪。Truist 上调 MBX Biosciences 目标价</li>
<li>积极情绪：MBX 发布了肥胖组合的更新，显示 MBX-4291 的早期第一阶段数据，包括第一组在 8 周内平均减重 7% 的结果，并支持潜在的每月一次给药，这可能增强投资者对公司管线的信心。MBX 肥胖组合更新和第一阶段数据</li>
<li>中性情绪：Lifesci Capital 做出了混合的预测调整：它将一些 2026 年季度预估下调，同时上调了第二季度的预估，并保持 <strong>强买</strong> 评级。这些修订表明预期仍在演变，但该公司整体上仍持建设性态度。</li>
</ul>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师评级上调与下调</h2>
</div><p>A number of equities analysts have commented on MBX shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Citigroup restated an &#34;outperform&#34; rating on shares of MBX Biosciences in a research note on Tuesday. Lifesci Capital upgraded shares of MBX Biosciences to a &#34;strong-buy&#34; rating in a research note on Tuesday, March 31st. TD Cowen restated a &#34;buy&#34; rating on shares of MBX Biosciences in a research note on Thursday, March 12th. Finally, Barclays upped their target price on shares of MBX Biosciences from $66.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $60.22.</p>
<div class="lb-trans"><p>多位股票分析师对 MBX 股票发表了评论。Weiss Ratings 在 4 月 21 日的报告中重申了对 MBX Biosciences 股票的 &#34;卖出（d-）&#34; 评级。花旗集团在周二的研究报告中重申了对 MBX Biosciences 股票的 &#34;跑赢大盘&#34; 评级。Lifesci Capital 在 3 月 31 日的研究报告中将 MBX Biosciences 股票的评级上调至 &#34;强买&#34;。TD Cowen 在 3 月 12 日的研究报告中重申了对 MBX Biosciences 股票的 &#34;买入&#34; 评级。最后，巴克莱在周二的研究报告中将 MBX Biosciences 股票的目标价从 66.00 美元上调至 70.00 美元，并给予该公司 &#34;增持&#34; 评级。一位投资分析师对该股票给予了强买评级，十位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 &#34;适度买入&#34;，平均目标价为 60.22 美元。</p>
</div><p><strong>View Our Latest Stock Report on MBX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 MBX 股票报告</strong></p>
</div><h2>MBX Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>MBX Biosciences 股票表现</h2>
</div><p>The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -16.74 and a beta of 0.78. The business's 50 day moving average price is $31.18 and its 200-day moving average price is $31.40.</p>
<div class="lb-trans"><p>该公司的市值为 17.6 亿美元，市盈率为-16.74，贝塔值为 0.78。该公司的 50 日移动平均价格为 31.18 美元，200 日移动平均价格为 31.40 美元。</p>
</div><p>MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its earnings results on Thursday, March 12th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.64) by $0.15. On average, analysts forecast that MBX Biosciences, Inc. will post -2.9 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MBX Biosciences（纳斯达克代码：MBX - 获取免费报告）最近在 3 月 12 日发布了其财报。该公司报告每股收益（EPS）为-0.49 美元，超出分析师的共识预期-0.64 美元，超出幅度为 0.15 美元。分析师平均预测 MBX Biosciences, Inc. 本财年每股收益为-2.9 美元。</p>
</div><h2>Insider Buying and Selling at MBX Biosciences</h2>
<div class="lb-trans"><h2>MBX Biosciences 的内部买卖</h2>
</div><p>In other MBX Biosciences news, CEO P. Kent Hawryluk acquired 18,500 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was acquired at an average price of $28.41 per share, with a total value of $525,585.00. Following the transaction, the chief executive officer directly owned 486,777 shares in the company, valued at approximately $13,829,334.57. This represents a 3.95% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this link.</p>
<div class="lb-trans"><p>在其他 MBX Biosciences 的新闻中，首席执行官 P. Kent Hawryluk 于 3 月 13 日收购了 18,500 股该股票。该股票的收购均价为每股 28.41 美元，总价值为 525,585.00 美元。交易后，首席执行官直接持有该公司 486,777 股股票，价值约为 13,829,334.57 美元。这代表了其持股比例的 3.95% 的增长。该收购在向证券交易委员会的备案中披露，相关信息可通过此链接访问。</p>
</div><h2>Institutional Investors Weigh In On MBX Biosciences</h2>
<div class="lb-trans"><h2>机构投资者对 MBX Biosciences 的看法</h2>
</div><p>A number of institutional investors have recently modified their holdings of MBX. Geode Capital Management LLC grew its position in shares of MBX Biosciences by 27.0% during the 2nd quarter. Geode Capital Management LLC now owns 348,447 shares of the company's stock valued at $3,976,000 after buying an additional 73,989 shares during the last quarter. Rhumbline Advisers grew its position in shares of MBX Biosciences by 171.6% during the 2nd quarter. Rhumbline Advisers now owns 23,662 shares of the company's stock valued at $270,000 after buying an additional 14,950 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of MBX Biosciences during the 2nd quarter valued at about $135,000. The Manufacturers Life Insurance Company grew its position in shares of MBX Biosciences by 73.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 87,097 shares of the company's stock valued at $994,000 after buying an additional 36,987 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of MBX Biosciences by 40.3% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,329 shares of the company's stock valued at $106,000 after buying an additional 2,682 shares during the last quarter.</p>
<div class="lb-trans"><p>多家机构投资者最近调整了对 MBX 的持股。Geode Capital Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前拥有 348,447 股该公司股票，价值 397.6 万美元，此前在上个季度又购买了 73,989 股。Rhumbline Advisers 在第二季度将其在 MBX Biosciences 的持股增加了 171.6%。Rhumbline Advisers 目前拥有 23,662 股该公司股票，价值 27 万美元，此前在上个季度又购买了 14,950 股。XTX Topco Ltd 在第二季度购买了价值约 135,000 美元的 MBX Biosciences 新股份。制造商人寿保险公司在第二季度将其在 MBX Biosciences 的持股增加了 73.8%。制造商人寿保险公司目前拥有 87,097 股该公司股票，价值 994,000 美元，此前在上个季度又购买了 36,987 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 MBX Biosciences 的持股增加了 40.3%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 9,329 股该公司股票，价值 106,000 美元，此前在上个季度又购买了 2,682 股。</p>
</div><h2>MBX Biosciences Company Profile</h2>
<div class="lb-trans"><h2>MBX Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.</p>
<div class="lb-trans"><p>我们是一家临床阶段的生物制药公司，专注于发现和开发用于治疗内分泌和代谢疾病的新型精准肽疗法。我们的公司由全球领先的专家创立，采用变革性的方法进行肽药物的设计和开发。利用这一专业知识，我们设计了专有的精准内分泌肽™（PEPTM）平台，以克服未修饰和修饰肽疗法的关键限制，并改善临床结果，简化患者的疾病管理。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than MBX Biosciences</li>
<li>Navy Catalyst Ignites Odysight’s Growth Engine</li>
<li>AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?</li>
<li>Axon Surged After Earnings and Is Still Down Over 50% From Highs</li>
<li>The Event That Could Redefine Apple’s Summer Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 MBX Biosciences</li>
<li>海军催化剂点燃 Odysight 的增长引擎</li>
<li>AST SpaceMobile 因银河第一季度业绩不佳而暴跌：垂直整合能拯救这家 SpaceX 竞争对手吗？</li>
<li>Axon 在财报发布后大幅上涨，但仍比高点下跌超过 50%</li>
<li>可能重新定义苹果夏季反弹的事件</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MBX Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元于 MBX Biosciences 吗？</h2>
</div><p>Before you consider MBX Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MBX Biosciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MBX Biosciences 并不在名单上。</p>
</div><p>While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MBX Biosciences 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MBX Biosciences（NASDAQ:MBX）股价下跌 8.8% - 事情经过如下